ACL
vs
S
S&P/ASX 300
ACL
Over the past 12 months, ACL has outperformed S&P/ASX 300, delivering a return of +12% compared to S&P/ASX 300's +1% growth.
Stocks Performance
ACL vs S&P/ASX 300
Performance Gap
ACL vs S&P/ASX 300
Performance By Year
ACL vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Australian Clinical Labs Ltd
Glance View
Australian Clinical Labs is one of Australia’s large medical pathology companies. It collects and tests blood, tissue, urine, and other samples to help doctors diagnose illness, monitor treatment, and screen for disease. Its main customers are hospitals, GPs, specialists, and other healthcare providers that need reliable lab results for patient care. The company makes money by charging for pathology tests. In practice, a large share of that work is funded through Medicare or paid by private health insurers, hospitals, and patients depending on the service and setting. Australian Clinical Labs sits in the middle of the healthcare system: it does not sell drugs or devices, but it provides the test results that many medical decisions depend on. What makes its business model distinct is the mix of scale, logistics, and specialist lab expertise. Samples must be collected, transported, processed, and reported quickly and accurately, so the company relies on a network of collection points, labs, and trained staff rather than a physical retail product. That creates a repeat-service business tied to ongoing healthcare demand rather than one-off purchases.
